Novo Nordisk Lifts Curbs on Wegovy Prescriptions in the U.S., …
Nov 6, 2024 · COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, …
COPENHAGEN, Nov 6 (Reuters) - Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was...
Novo Nordisk's Blockbuster Wegovy Drug Sales Beat …
Nov 6, 2024 · Novo Nordisk's blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen demand ...
Novo Nordisk's Blockbuster Wegovy Sales Beat Expectations — …
Nov 6, 2024 · Global News Select Novo Nordisk's Blockbuster Wegovy Sales Beat Expectations — Update ... The Danish pharmaceutical giant said sales of Wegovy surged 79% on year to 17.3 billion Danish kroner ...
Strong Wegovy revenue growth for Novo Nordisk but shares dip
Nov 6, 2024 · Novo Nordisk has reported net Q3 profits of $3.94bn (DKr27.3bn) fuelled by better-than-expected sales for its blockbuster weight loss drug Wegovy (semaglutide).. Sales of the glucagon-like peptide receptor agonist (GLP-1RA) hit $2.5bn in the third quarter, a 79% increase compared to the same period in 2023, as per a 6 November press release.
Ozempic, Wegovy maker Novo Nordisk faces hearing over high …
Sep 24, 2024 · WASHINGTON — Sen. Bernie Sanders, I-Vt., on Tuesday extracted a meager commitment from Novo Nordisk CEO Lars Fruergaard Jørgensen to meet with pharmacy benefits managers to discuss lowering the...
News Details - Novo Nordisk
Jul 25, 2024 · The SELECT data demonstrated that in addition to helping people manage their weight, Wegovy ® has the potential to protect lives by reducing the risks of major adverse cardiovascular events”, said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk.
News details - Novo Nordisk
PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy ® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along ...
News Details - Novo Nordisk
Mar 8, 2024 · "We are very pleased that Wegovy ® is now approved in the US as the first therapy to help people manage their weight and reduce cardiovascular risks," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk.
News details - Novo Nordisk
PLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti …